Regeneron Pharmaceuticals, Inc. (ETR:RGO)

Germany flag Germany · Delayed Price · Currency is EUR
634.00
-9.20 (-1.43%)
At close: Jan 28, 2026
30.64%
Market Cap64.03B -12.9%
Revenue (ttm)12.22B +1.0%
Net Income3.84B +2.1%
EPS35.33 +8.2%
Shares Outn/a
PE Ratio16.69
Forward PE15.39
Dividend3.40 (0.54%)
Ex-Dividend DateNov 20, 2025
Volume27
Average Volume136
Open641.20
Previous Close643.20
Day's Range634.00 - 641.20
52-Week Range464.70 - 702.60
Betan/a
RSI40.71
Earnings DateJan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Pharmaceutical Preparations
Founded 1988
Employees 15,222
Stock Exchange Deutsche Börse Xetra
Ticker Symbol RGO
Full Company Profile

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD Financial Statements